Pharming Group N.V. Files Form 6-K

TL;DR

Pharming Group N.V. just dropped a 6-K filing with a press release, check it out.

AI Summary

Pharming Group N.V. filed a Form 6-K on May 21, 2024, to furnish a press release dated May 21, 2024, as Exhibit 99.1. The filing does not contain specific financial figures or operational details within the provided text, but indicates a report for the month of May 2024.

Why It Matters

This filing serves as an update from Pharming Group N.V. to the SEC, providing information to investors and the public regarding the company's activities.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• 001-39822 (dollar_amount) — Commission File Number
• May 21, 2024 (date) — Filing Date and Press Release Date

FAQ

Filing Documents

• pharminggroupreportsonresu.htm (6-K) — 21KB
• logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
• 0001828316-24-000025.txt ( ) — 164KB

From the Filing

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated May 21, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By s Sijmen de Vries Name Sijmen de Vries Title CEO Date May 21, 2024 Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders Leiden, the Netherlands, May 21, 2024 Pharming Group N.V. ("Pharming" or "the Company") (Euronext PHARMNasdaq PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. The shareholders approved the proposals to reappoint Ms. Barbara Yanni (agenda item 4.a) and Mr. Mark Pykett (agenda item 4.b), upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. In addition, the proposals for the adoption of the updated Remuneration Policy for members of the Board of Directors (agenda item 3), the authorization for the Board of Directors to issue shares andor options (agenda item 5) and the authorization for the Board of Directors to repurchase shares (agenda item 6) were approved by the shareholders. A recording of the webcast, presentation slides from today's AGM, and more details regarding agenda items are available on the Company's website in the Investor Relations section. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam PHARMNasdaq PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics that are in clinical development. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. For further public information, contact Pharming Group, Leiden, The Netherlands Michael Levitan, VP Investor Relations Corporate Communications T +1 (908) 705 1696 E investorpharming.com FTI Consulting, London, UK Victoria Foster MitchellAlex ShawAmy Byrne T +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, The Netherlands Leon Melens T +31 6 53 81 64 27 E pharminglifespring.nl

View Full Filing

View this 6-K filing on SEC EDGAR